Article Text

PDF
THU0499 Hm71224, A Novel Oral BTK Inhibitor, Inhibits Human Immune Cell Activation: New Drug Candidate to Treat B-Cell Associated Autoimmune Diseases
  1. J.K. Park1,
  2. J.A. Park1,
  3. Y.J. Lee1,
  4. J. Song2,
  5. J.I. Oh2,
  6. Y.-M. Lee2,
  7. K.H. Suh2,
  8. J. Son2,
  9. E.B. Lee1
  1. 1Internal Medicine, Seoul National University Hospital, Seoul
  2. 2Hanmi Research Center, Hanmi Pharm. Co., Ltd., Hwaseong, Korea, Republic Of

Abstract

Background Bruton tyrosine kinase (BTK), a Tec family kinase, is involved in B cell activation and osteoclast formation. As BTK plays a central role in B cell receptor (BCR) signaling and B cell development, BTK might be an attractive therapeutic target for autoimmune diseases including rheumatoid arthritis (RA) [1–3].

Objectives To investigate the effects of HM7122, a novel BTK inhibitor, on human B cell activation and osteoclast formation.

Methods In vitro biochemical inhibition assay was performed using Invitrogen kinase assay. Peripheral blood mononuclear cells (PBMCs) from healthy controls were activated with anti-human IgM in increasing concentrations of HM71224. Phosphorylationof BTK and its down-stream signaling molecules PLCγ2 and ERK were examined using phospho-flow and phospho-blots. The BTK occupancy was measured in PBMCs using ELISA. The expression of B cell activation marker CD40, CD69 and CD86 were examined by flow cytometry. Osteoclasts were generated from isolated monocytes in the presence of M-CSF and RANKL and the inhibition of osteoclast generation by HM71224 was examined.

Results In vitro, HM71224 effectively bound to BTK (IC50 =2nM) but not to STAT5 (IC50 >1000 nM), STAT6 (IC50 =445 nM) and EGFR (IC50 =800 nM). HM71224 blocked phosphorylation of BTK, PLCγ2 and ERK (IC50 =1nM, 1nM, and 100 nM, respectively). The BTK occupancy in human PBMCs showed an effective binding of HM71224 to BTK protein (IC50 =69.9±14 nM). Upregulation of the activation marker CD40, CD69 and CD86 on stimulated human B cells were inhibited by HM71224 in a dose-dependent manner (Figure A). Furthermore, osteoclast formation was suppressed in the presence of HM71224 as well (Figure B).

Conclusions HM71224 is a novel BTK inhibitor that effectively inhibits B cell activation and osteoclastogenesis. HM71224 might offer a new therapeutic option to treat autoimmune diseases associated with B cell activation.

References

  1. Edwards J.C.W. et al, B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology, 2006, 6: 394-403.

  2. Rickert R.C. New insights into pre-BCR and BCR signaling with relevance to B cell malignancies. Nature Reviews Immunology, 2013, 13:578-591.

  3. Swanson D.C. et al, Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nature Reviews Rheumatology, 2009, 5: 317-324.

Disclosure of Interest : J. K. Park: None declared, J. A. Park: None declared, Y. J. Lee: None declared, J. Song: None declared, J. I. Oh: None declared, Y.-M. Lee: None declared, K. H. Suh: None declared, J. Son: None declared, E. B. Lee Grant/research support: Hanmi Pharm Co Ltd

DOI 10.1136/annrheumdis-2014-eular.2783

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.